Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 632

Results For "IP"

10475 News Found

Biocon Biologics' new mAbs facility receives EU GMP Certification for bBevacizumab
News | April 29, 2023

Biocon Biologics' new mAbs facility receives EU GMP Certification for bBevacizumab

This approval reflects Biocon Biologics' compliance with the highest international regulatory standards


RPG Life Sciences posts Q4 revenue at Rs 118.49 Cr
News | April 29, 2023

RPG Life Sciences posts Q4 revenue at Rs 118.49 Cr

Revenue from operations at Rs 512.81 crores registered a growth of 17% Y-o-Y for full year FY23


Atul appoints Rangaswamy Iyer as Independent Director
People | April 29, 2023

Atul appoints Rangaswamy Iyer as Independent Director

The appointment is effective from May 01, 2023 for five years


TPAG organizes Thalassemia & SCD prevention discussion
News | April 29, 2023

TPAG organizes Thalassemia & SCD prevention discussion

The policymakers, doctors and, patient bodies discuss ways to implement thalassemia control programme nationally


Laurus Labs Q4 FY23 consolidated PAT drops to to Rs. 102.98 Cr
News | April 28, 2023

Laurus Labs Q4 FY23 consolidated PAT drops to to Rs. 102.98 Cr

Q4 results was challenging driven by steep fall in CDMO revenues and higher upfront cost of Capex projects and R&D projects


Yuyu Pharma unveils the results of its studies for its dry eye treatment peptide
News | April 28, 2023

Yuyu Pharma unveils the results of its studies for its dry eye treatment peptide

The YP-P10 pre-clinical head-to-head study, jointly conducted by five people including Dr. Kyungho Park of Naason Science


Yasmin and Mirena to take back seat from Bayer’s future drug strategy, says GlobalData
News | April 28, 2023

Yasmin and Mirena to take back seat from Bayer’s future drug strategy, says GlobalData

The news on a shift in its focus comes after the refinement of Bayer’s early innovation framework


Biocon approves NCD issue
News | April 27, 2023

Biocon approves NCD issue

The return profile of NCDs is linked to BBL share price subject to minimum IRR of 12%.


Syngene International posts Q4 FY2023 consolidated profit at Rs. 178.7 Cr
News | April 27, 2023

Syngene International posts Q4 FY2023 consolidated profit at Rs. 178.7 Cr

The company has posted net profit of Rs.464.4 crores for the Financial Year ended March 31, 2023